sharonyim的个人主页 - 老虎社区

sharonyim

sharonyim

暂无个人介绍

IP属地：未知

166关注

21粉丝

0主题

0勋章

2021-06-18

//@共同投资: 难看?请问好看的走势是什么？一直能稳住50以上不下去，这就说明市场认可这个价格。go to the moon$AMC院线(AMC)$

@趋势队长:$AMC院线(AMC)$ amc已经废了，走势很难看，现在还敢做多的真牛$黑莓(BB)$ $Sundial Growers Inc.(SNDL)$ $Global Telecom & Technology(GTT)$ $游戏驿站(GME)$

2021-06-17

[微笑] [微笑] [微笑]

2021-06-16

$AMC Entertainment(AMC)$[保佑] [保佑] [保佑]

2021-06-14

[微笑] [微笑] [微笑]

抱歉，原内容已删除

2021-05-25

pls comment and like post[微笑]

抱歉，原内容已删除

2021-05-08

[微笑]

抱歉，原内容已删除

2021-05-06

[微笑] [微笑] [微笑] [微笑]

抱歉，原内容已删除

2021-05-03

pls help to.comment and like . thanks[微笑]

抱歉，原内容已删除

2021-05-01

[开心] [开心] [开心]

抱歉，原内容已删除

2021-04-27

buy ?[微笑]

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3581852273201777,"uuid":"3581852273201777","gmtCreate":1618759092541,"gmtModify":1621218987591,"name":"sharonyim","pinyin":"sharonyim","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":21,"headSize":166,"tweetSize":136,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":166632546,"gmtCreate":1624005411885,"gmtModify":1634024236450,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"//<a href=\"https://laohu8.com/U/3542667587101580\">@共同投资</a>: 难看?请问好看的走势是什么？一直能稳住50以上不下去，这就说明市场认可这个价格。go to the moon<a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a>","listText":"//<a href=\"https://laohu8.com/U/3542667587101580\">@共同投资</a>: 难看?请问好看的走势是什么？一直能稳住50以上不下去，这就说明市场认可这个价格。go to the moon<a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a>","text":"//@共同投资: 难看?请问好看的走势是什么？一直能稳住50以上不下去，这就说明市场认可这个价格。go to the moon$AMC院线(AMC)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166632546","repostId":"163989566","repostType":1,"repost":{"id":163989566,"gmtCreate":1623856648755,"gmtModify":1623920075541,"author":{"id":"3521339628608760","authorId":"3521339628608760","name":"趋势队长","avatar":"https://static.tigerbbs.com/a126f572eafb02336cabf7f7a75e6712","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a> amc已经废了，走势很难看，现在还敢做多的真牛<a target=\"_blank\" href=\"https://laohu8.com/S/BB\">$黑莓(BB)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/GTT\">$Global Telecom &amp; Technology(GTT)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/GME\">$游戏驿站(GME)$</a>","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a> amc已经废了，走势很难看，现在还敢做多的真牛<a target=\"_blank\" href=\"https://laohu8.com/S/BB\">$黑莓(BB)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/GTT\">$Global Telecom &amp; Technology(GTT)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/GME\">$游戏驿站(GME)$</a>","text":"$AMC院线(AMC)$ amc已经废了，走势很难看，现在还敢做多的真牛$黑莓(BB)$ $Sundial Growers Inc.(SNDL)$ $Global Telecom & Technology(GTT)$ $游戏驿站(GME)$","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163989566","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":880,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":161591122,"gmtCreate":1623933313266,"gmtModify":1634025714456,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;","listText":"[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;","text":"[微笑] [微笑] [微笑]","images":[{"img":"https://static.tigerbbs.com/a56ba061c9536dc7ce6271ab37eff90b","width":"1080","height":"2037"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161591122","isVote":1,"tweetType":1,"viewCount":579,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":169060011,"gmtCreate":1623809333133,"gmtModify":1634027788298,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>[保佑]&nbsp;[保佑]&nbsp;[保佑]&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>[保佑]&nbsp;[保佑]&nbsp;[保佑]&nbsp;","text":"$AMC Entertainment(AMC)$[保佑] [保佑] [保佑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169060011","isVote":1,"tweetType":1,"viewCount":329,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":185473391,"gmtCreate":1623670574913,"gmtModify":1634030411724,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;","listText":"[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;","text":"[微笑] [微笑] [微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185473391","repostId":"2141453253","repostType":4,"isVote":1,"tweetType":1,"viewCount":311,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":138026434,"gmtCreate":1621902014828,"gmtModify":1634185707596,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"pls comment and like post[微笑]&nbsp;","listText":"pls comment and like post[微笑]&nbsp;","text":"pls comment and like post[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":8,"repostSize":0,"link":"https://laohu8.com/post/138026434","repostId":"1162260293","repostType":4,"isVote":1,"tweetType":1,"viewCount":609,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":107991339,"gmtCreate":1620437279921,"gmtModify":1634198804026,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/107991339","repostId":"1106240370","repostType":4,"isVote":1,"tweetType":1,"viewCount":675,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":102726943,"gmtCreate":1620255688882,"gmtModify":1634206706899,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;","listText":"[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;","text":"[微笑] [微笑] [微笑] [微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/102726943","repostId":"2133255365","repostType":4,"isVote":1,"tweetType":1,"viewCount":742,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":108106186,"gmtCreate":1620003146045,"gmtModify":1634208651625,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"pls help to.comment and like . thanks[微笑]&nbsp;","listText":"pls help to.comment and like . thanks[微笑]&nbsp;","text":"pls help to.comment and like . thanks[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":9,"repostSize":0,"link":"https://laohu8.com/post/108106186","repostId":"1167373947","repostType":4,"isVote":1,"tweetType":1,"viewCount":913,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":103748018,"gmtCreate":1619826955334,"gmtModify":1634209714846,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[开心]&nbsp;[开心]&nbsp;[开心]&nbsp;","listText":"[开心]&nbsp;[开心]&nbsp;[开心]&nbsp;","text":"[开心] [开心] [开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/103748018","repostId":"1138497242","repostType":4,"isVote":1,"tweetType":1,"viewCount":525,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":374492331,"gmtCreate":1619475085323,"gmtModify":1634273253396,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"buy ?[微笑]&nbsp;","listText":"buy ?[微笑]&nbsp;","text":"buy ?[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/374492331","repostId":"1194765641","repostType":4,"isVote":1,"tweetType":1,"viewCount":361,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":138026434,"gmtCreate":1621902014828,"gmtModify":1634185707596,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"pls comment and like post[微笑]&nbsp;","listText":"pls comment and like post[微笑]&nbsp;","text":"pls comment and like post[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":8,"repostSize":0,"link":"https://laohu8.com/post/138026434","repostId":"1162260293","repostType":4,"repost":{"id":"1162260293","pubTimestamp":1621900762,"share":"https://www.laohu8.com/m/news/1162260293?lang=&edition=full","pubTime":"2021-05-25 07:59","market":"us","language":"en","title":"Manufacturing could return to China, as Covid cases spike in India and Vietnam","url":"https://stock-news.laohu8.com/highlight/detail?id=1162260293","media":"cnbc","summary":"KEY POINTS\n\nPreviously, the U.S.-China trade war caused companies to move their supply chains out of","content":"<div>\n<p>KEY POINTS\n\nPreviously, the U.S.-China trade war caused companies to move their supply chains out of China. As a result, countries like Vietnam and India benefited as companies set up shop there.\nBut ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/25/supply-chains-may-return-to-china-amid-covid-resurgence-in-india-vietnam.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Manufacturing could return to China, as Covid cases spike in India and Vietnam</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nManufacturing could return to China, as Covid cases spike in India and Vietnam\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 07:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/25/supply-chains-may-return-to-china-amid-covid-resurgence-in-india-vietnam.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nPreviously, the U.S.-China trade war caused companies to move their supply chains out of China. As a result, countries like Vietnam and India benefited as companies set up shop there.\nBut ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/25/supply-chains-may-return-to-china-amid-covid-resurgence-in-india-vietnam.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"399001":"深证成指","399006":"创业板指","SPY":"标普500ETF",".DJI":"道琼斯","000001.SH":"上证指数",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.cnbc.com/2021/05/25/supply-chains-may-return-to-china-amid-covid-resurgence-in-india-vietnam.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162260293","content_text":"KEY POINTS\n\nPreviously, the U.S.-China trade war caused companies to move their supply chains out of China. As a result, countries like Vietnam and India benefited as companies set up shop there.\nBut the situation is changing, and supply chains could pivot back to China as cases spike in India and Vietnam, according to Zhang Zhiwei, chief economist at Pinpoint Asset Management.\n\nThe Covid-19 resurgence in some parts of Asia could lead to a change in fortunes for China, according to an economist.\nPreviously, the U.S.-China trade war caused companies to move their supply chains out of China, shifting their production and distribution networks for products and services. As a result, countries like Vietnam and India benefited as companies moved to set up shop in their countries.\nBut the situation appears to be changing, and supply chains could pivot back to China as cases spike in India and Vietnam, according to Zhang Zhiwei, chief economist at Pinpoint Asset Management.\n\"Before the pandemic, we saw factories moving out of China — Samsung, Foxconn these big name companies — setting up factories in Vietnam, India,\" he told CNBC's \"Street Signs Asia\" on Monday.\nThe spike in cases in those two countries has forced factories owned by Taiwanese contract manufacturer Foxconn, a major Apple supplier, to shut down facilities in India and Vietnam, he said.\n\"This could put the relocation of supply chains on hold for quite some time. The key issue here is that international travel is suspended, so multinational companies can't send their staff to India and Vietnam to set up new factories,\" Zhang added.\nCases in India surged to record-breaking highs in April andshows little signs of abating significantly—economists have predicted the South Asian economy will likely contract this quarter.\nIn Vietnam, the northern province of Bac Giang on Tuesday ordered four industrial parks — including three that house production facilities of Taiwan's Foxconn— to temporarily shut down due to an outbreak of Covid-19.\nThe situation could benefit China, Zhang suggested. However, he pointed out that the extent of how much China could stand to gain will depend on how long the situation in India and Vietnam continues for.\nRight now, export growth in China is between 20% to 40% a month, he said. If the factories in India and Vietnam return to production very soon, China's exports would be expected to slow down in the second half of the year as companies move their manufacturing to those two countries.\n\"But if supply chain (in India and Vietnam) is disrupted for a long time, we could see this kind of 20%, 30% export growth (in China) to continue into next year,\" Zhang said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":609,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":108106186,"gmtCreate":1620003146045,"gmtModify":1634208651625,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"pls help to.comment and like . thanks[微笑]&nbsp;","listText":"pls help to.comment and like . thanks[微笑]&nbsp;","text":"pls help to.comment and like . thanks[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":9,"repostSize":0,"link":"https://laohu8.com/post/108106186","repostId":"1167373947","repostType":4,"isVote":1,"tweetType":1,"viewCount":913,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":103748018,"gmtCreate":1619826955334,"gmtModify":1634209714846,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[开心]&nbsp;[开心]&nbsp;[开心]&nbsp;","listText":"[开心]&nbsp;[开心]&nbsp;[开心]&nbsp;","text":"[开心] [开心] [开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/103748018","repostId":"1138497242","repostType":4,"repost":{"id":"1138497242","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1619794882,"share":"https://www.laohu8.com/m/news/1138497242?lang=&edition=full","pubTime":"2021-04-30 23:01","market":"us","language":"en","title":"Twitter may struggle to replicate bumper 2020 growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1138497242","media":"Reuters","summary":"Twitter Inc will struggle to replicate a bumper 2020 dominated by the U.S. political battles, civil ","content":"<p>Twitter Inc will struggle to replicate a bumper 2020 dominated by the U.S. political battles, civil unrest and the COVID-19 crisis as people venture out following vaccine rollouts, Wall Street analysts said on Friday.</p><p>The lifting of restrictions as people get vaccinated has largely seen benefiting other digital ad firms such as Facebook Inc and Alphabet Inc’s Google whose stocks soared after reporting blockbuster results this week.</p><p>Not so with Twitter. Shares sank more than 12% on Friday after the social media company reported first-quarter revenue and user numbers mostly in line with analyst estimates and warned the current quarter could be its worse as it eyed a weaker 2021.</p><p>“The company’s weak future guidance suggests that repeating this performance will be extremely difficult,” said Haris Anwar, senior analyst at Investing.com, adding that more people will look to engage in offline activities as the vaccine rollouts pick up.</p><p>Although other tech companies have warned of a drop in users this year, they are still upbeat on ad spending as marketers try to target consumers eager to spend and travel after being locked indoors for over a year.</p><p>“Twitter doesn’t seem well positioned to actually capture the most dynamic part of the digital advertising economy as they lack both sufficient scale of users and the first party data signals that attract performance based marketers,” said Michael Nathanson, senior research analyst at MoffetNathanson LLC.</p><p>A vow to focus on new products and features by Twitter did little to allay investor concerns on Friday.</p><p>However, some analysts found the company’s current-quarter revenue forecast conservative as they expect newer app features and return of live events to boost user engagement and monetization in coming months.</p><p>At least eight brokerages cut their price targets on Twitter after the company forecast tepid revenue growth for the second quarter.</p><p>Of the 40 analysts covering the stock, 29 have a “hold” or lower rating and the rest have a “buy” or higher rating. The current median price target on the stock is $70, as per Refinitiv data. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Twitter may struggle to replicate bumper 2020 growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwitter may struggle to replicate bumper 2020 growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-04-30 23:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Twitter Inc will struggle to replicate a bumper 2020 dominated by the U.S. political battles, civil unrest and the COVID-19 crisis as people venture out following vaccine rollouts, Wall Street analysts said on Friday.</p><p>The lifting of restrictions as people get vaccinated has largely seen benefiting other digital ad firms such as Facebook Inc and Alphabet Inc’s Google whose stocks soared after reporting blockbuster results this week.</p><p>Not so with Twitter. Shares sank more than 12% on Friday after the social media company reported first-quarter revenue and user numbers mostly in line with analyst estimates and warned the current quarter could be its worse as it eyed a weaker 2021.</p><p>“The company’s weak future guidance suggests that repeating this performance will be extremely difficult,” said Haris Anwar, senior analyst at Investing.com, adding that more people will look to engage in offline activities as the vaccine rollouts pick up.</p><p>Although other tech companies have warned of a drop in users this year, they are still upbeat on ad spending as marketers try to target consumers eager to spend and travel after being locked indoors for over a year.</p><p>“Twitter doesn’t seem well positioned to actually capture the most dynamic part of the digital advertising economy as they lack both sufficient scale of users and the first party data signals that attract performance based marketers,” said Michael Nathanson, senior research analyst at MoffetNathanson LLC.</p><p>A vow to focus on new products and features by Twitter did little to allay investor concerns on Friday.</p><p>However, some analysts found the company’s current-quarter revenue forecast conservative as they expect newer app features and return of live events to boost user engagement and monetization in coming months.</p><p>At least eight brokerages cut their price targets on Twitter after the company forecast tepid revenue growth for the second quarter.</p><p>Of the 40 analysts covering the stock, 29 have a “hold” or lower rating and the rest have a “buy” or higher rating. The current median price target on the stock is $70, as per Refinitiv data. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWTR":"Twitter"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138497242","content_text":"Twitter Inc will struggle to replicate a bumper 2020 dominated by the U.S. political battles, civil unrest and the COVID-19 crisis as people venture out following vaccine rollouts, Wall Street analysts said on Friday.The lifting of restrictions as people get vaccinated has largely seen benefiting other digital ad firms such as Facebook Inc and Alphabet Inc’s Google whose stocks soared after reporting blockbuster results this week.Not so with Twitter. Shares sank more than 12% on Friday after the social media company reported first-quarter revenue and user numbers mostly in line with analyst estimates and warned the current quarter could be its worse as it eyed a weaker 2021.“The company’s weak future guidance suggests that repeating this performance will be extremely difficult,” said Haris Anwar, senior analyst at Investing.com, adding that more people will look to engage in offline activities as the vaccine rollouts pick up.Although other tech companies have warned of a drop in users this year, they are still upbeat on ad spending as marketers try to target consumers eager to spend and travel after being locked indoors for over a year.“Twitter doesn’t seem well positioned to actually capture the most dynamic part of the digital advertising economy as they lack both sufficient scale of users and the first party data signals that attract performance based marketers,” said Michael Nathanson, senior research analyst at MoffetNathanson LLC.A vow to focus on new products and features by Twitter did little to allay investor concerns on Friday.However, some analysts found the company’s current-quarter revenue forecast conservative as they expect newer app features and return of live events to boost user engagement and monetization in coming months.At least eight brokerages cut their price targets on Twitter after the company forecast tepid revenue growth for the second quarter.Of the 40 analysts covering the stock, 29 have a “hold” or lower rating and the rest have a “buy” or higher rating. The current median price target on the stock is $70, as per Refinitiv data.","news_type":1},"isVote":1,"tweetType":1,"viewCount":525,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":107991339,"gmtCreate":1620437279921,"gmtModify":1634198804026,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/107991339","repostId":"1106240370","repostType":4,"repost":{"id":"1106240370","pubTimestamp":1620432184,"share":"https://www.laohu8.com/m/news/1106240370?lang=&edition=full","pubTime":"2021-05-08 08:03","market":"us","language":"en","title":"Pfizer CEO opposes U.S. call to waive Covid vaccine patents, cites manufacturing and safety issues","url":"https://stock-news.laohu8.com/highlight/detail?id=1106240370","media":"CNBC","summary":"KEY POINTSPfizer CEO Albert Bourla warned Friday that waiving patent protections for Covid vaccines ","content":"<div>\n<p>KEY POINTSPfizer CEO Albert Bourla warned Friday that waiving patent protections for Covid vaccines would set off a worldwide race for raw materials that threatens the safe and efficient manufacturing...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/07/pfizer-ceo-biden-backed-covid-vaccine-patent-waiver-will-cause-problems.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer CEO opposes U.S. call to waive Covid vaccine patents, cites manufacturing and safety issues</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer CEO opposes U.S. call to waive Covid vaccine patents, cites manufacturing and safety issues\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-08 08:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/07/pfizer-ceo-biden-backed-covid-vaccine-patent-waiver-will-cause-problems.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTSPfizer CEO Albert Bourla warned Friday that waiving patent protections for Covid vaccines would set off a worldwide race for raw materials that threatens the safe and efficient manufacturing...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/07/pfizer-ceo-biden-backed-covid-vaccine-patent-waiver-will-cause-problems.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.cnbc.com/2021/05/07/pfizer-ceo-biden-backed-covid-vaccine-patent-waiver-will-cause-problems.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1106240370","content_text":"KEY POINTSPfizer CEO Albert Bourla warned Friday that waiving patent protections for Covid vaccines would set off a worldwide race for raw materials that threatens the safe and efficient manufacturing of Covid shots.The Biden administration endorsed the waiver proposal days earlier, in service of expanding vaccine distribution to lower-income nations currently being battered by the pandemic.But Bourla, whose company produces one of three vaccines approved for emergency use in the U.S., said he believes \"categorically\" that the waiver proposal will \"create more problems.\"PfizerCEO Albert Bourla warned Friday that waiving patent protections for Covid vaccines —a proposal President Joe Biden just endorsed— would set off a worldwide race for raw materials that threatens the safe and efficient manufacturing of Covid shots.The Biden administration said Wednesday it supports the limited waiver of intellectual property rules in service of expanding vaccine distribution to the lower-income nations currently being battered bythe pandemic.But Bourla, whose company produces one of three vaccines approved for emergency use in the U.S., said that he believes “categorically” that the waiver proposal will “create more problems.”“Currently, infrastructure is not the bottleneck for us manufacturing faster,” Bourla wrote in a dear colleagueletter posted on LinkedIn. “The restriction is the scarcity of highly specialized raw materials needed to produce our vaccine.”Pfizer’s vaccine requires 280 different materials and components that are sourced from 19 countries around the world, Bourla said. He contended that without patent protections, entities with much less experienced than Pfizer at manufacturing vaccines will start competing for the same ingredients.“Right now, virtually every single gram of raw material produced is shipped immediately into our manufacturing facilities and is converted immediately and reliably to vaccines that are shipped immediately around the world,” Bourla wrote.He predicted that the proposed waiver “threatens to disrupt the flow of raw materials.”“It will unleash a scramble for the critical inputs we require in order to make a safe and effective vaccine,” Bourla wrote.“Entities with little or no experience in manufacturing vaccines are likely to chase the very raw materials we require to scale our production, putting the safety and security of all at risk,” the CEO wrote.The White House referred CNBC’s outreach on Bourla’s post to the Office of U.S. Trade Representative, which did not immediately respond to a request for comment.World Trade Organization leaders have recently urged member nations to come to an agreement on the potential vaccine patent waivers. But even with the U.S. backing, a deal is hardly guaranteed, since the WTO’s rulings are based on consensus, requiring approval from all 164 members.Germany, a WTO member and the largest economy in Europe, came out against the waiver proposal on Thursday.BioNTech, which partnered with Pfizer in developing the vaccine, is based in Germany.Bourla on LinkedIn also expressed concern that the possible vaccine waivers “will disincentivize anyone else from taking a big risk.”“The recent rhetoric will not discourage us from continuing investing in science. But I am not sure if the same is true for the thousands of small biotech innovators that are totally dependent on accessing capital from investors who invest only on the premise that their intellectual property will be protected,” the CEO wrote.PhRMA, the pharmaceutical industry interest groups whosemember companies includePfizer andJohnson & Johnson, another U.S. vaccine provider, called the waiver proposal “an unprecedented step that will undermine our global response to the pandemic and compromise safety.”Meanwhile, CEO Stephane Bancel ofModerna, maker of the other U.S.-approved Covid shot, saidhe wasn’t concerned about the possible waivers.","news_type":1},"isVote":1,"tweetType":1,"viewCount":675,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":166632546,"gmtCreate":1624005411885,"gmtModify":1634024236450,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"//<a href=\"https://laohu8.com/U/3542667587101580\">@共同投资</a>: 难看?请问好看的走势是什么？一直能稳住50以上不下去，这就说明市场认可这个价格。go to the moon<a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a>","listText":"//<a href=\"https://laohu8.com/U/3542667587101580\">@共同投资</a>: 难看?请问好看的走势是什么？一直能稳住50以上不下去，这就说明市场认可这个价格。go to the moon<a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a>","text":"//@共同投资: 难看?请问好看的走势是什么？一直能稳住50以上不下去，这就说明市场认可这个价格。go to the moon$AMC院线(AMC)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166632546","repostId":"163989566","repostType":1,"repost":{"id":163989566,"gmtCreate":1623856648755,"gmtModify":1623920075541,"author":{"id":"3521339628608760","authorId":"3521339628608760","name":"趋势队长","avatar":"https://static.tigerbbs.com/a126f572eafb02336cabf7f7a75e6712","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a> amc已经废了，走势很难看，现在还敢做多的真牛<a target=\"_blank\" href=\"https://laohu8.com/S/BB\">$黑莓(BB)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/GTT\">$Global Telecom &amp; Technology(GTT)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/GME\">$游戏驿站(GME)$</a>","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a> amc已经废了，走势很难看，现在还敢做多的真牛<a target=\"_blank\" href=\"https://laohu8.com/S/BB\">$黑莓(BB)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/GTT\">$Global Telecom &amp; Technology(GTT)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/GME\">$游戏驿站(GME)$</a>","text":"$AMC院线(AMC)$ amc已经废了，走势很难看，现在还敢做多的真牛$黑莓(BB)$ $Sundial Growers Inc.(SNDL)$ $Global Telecom & Technology(GTT)$ $游戏驿站(GME)$","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163989566","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":880,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":161591122,"gmtCreate":1623933313266,"gmtModify":1634025714456,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;","listText":"[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;","text":"[微笑] [微笑] [微笑]","images":[{"img":"https://static.tigerbbs.com/a56ba061c9536dc7ce6271ab37eff90b","width":"1080","height":"2037"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161591122","isVote":1,"tweetType":1,"viewCount":579,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":169060011,"gmtCreate":1623809333133,"gmtModify":1634027788298,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>[保佑]&nbsp;[保佑]&nbsp;[保佑]&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>[保佑]&nbsp;[保佑]&nbsp;[保佑]&nbsp;","text":"$AMC Entertainment(AMC)$[保佑] [保佑] [保佑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169060011","isVote":1,"tweetType":1,"viewCount":329,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":102726943,"gmtCreate":1620255688882,"gmtModify":1634206706899,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;","listText":"[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;","text":"[微笑] [微笑] [微笑] [微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/102726943","repostId":"2133255365","repostType":4,"repost":{"id":"2133255365","pubTimestamp":1620225900,"share":"https://www.laohu8.com/m/news/2133255365?lang=&edition=full","pubTime":"2021-05-05 22:45","market":"us","language":"en","title":"Cathie Wood Loads Up on More Skillz Stock After Record Q1 Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2133255365","media":"Motley Fool","summary":"The star investment manager puts her money where her mouth is.","content":"<p>Mobile esports platform <b>Skillz</b> (NYSE:SKLZ) recorded yet another quarter of rising revenue, the 21st consecutive quarter in which revenue jumped year over year. And that was apparently enough for Wall Street's current investment guru, Cathie Wood, to load up again on its stock.</p>\n<p>Wood's ARK Invest exchange-traded funds (ETFs) added another 3.1 million shares of Skillz yesterday (Wood's ETFs report their buys and sales daily), giving her nearly 15.6 million shares in total of the competitive-gameplay specialist.</p>\n<p><img src=\"https://static.tigerbbs.com/d9dcd970e1b1e9ef66ed2200f7e27796\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Although Skillz saw its revenue rise in the first quarter, it also reported wider losses for the period, with adjusted EBITDA coming in at a loss of $31.1 million, compared to losses of $14.6 million a year ago.</p>\n<p>Still, the esports company was able to exceed its own expectations on paying monthly average users (MAUs), which came in at 467,000, some 17,000 more than it guided for last quarter. However, that was below the upper end of Wall Street's forecast of 469,000 MAUs.</p>\n<p>Last month, short-seller Eagle Eye Research issued a report questioning Skillz's revenue-recognition policies. Another short-seller, Wolfpack Research, questioned the value of its recent deal with the National Football League.</p>\n<p>Cathie Wood ended up coming to Skillz's defense, saying the allegations were \"either exaggerated or incorrect\" and stemmed from not understanding the esports company's business.</p>\n<p>Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b> (NYSEMKT:ARKW) now owns 7.05 million shares of Skillz; her <b>ARK Innovation</b> (NYSEMKT:ARKK) owns over 8.51 million shares.</p>\n<p>While her purchases are yet another vote of confidence for Skillz, they don't comprise a particularly large portion of her funds' portfolios, amounting to no more than 1.92% in either of the two funds.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Loads Up on More Skillz Stock After Record Q1 Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Loads Up on More Skillz Stock After Record Q1 Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-05 22:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/05/cathie-wood-loads-up-on-more-skillz-stock-after-re/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mobile esports platform Skillz (NYSE:SKLZ) recorded yet another quarter of rising revenue, the 21st consecutive quarter in which revenue jumped year over year. And that was apparently enough for Wall ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/05/cathie-wood-loads-up-on-more-skillz-stock-after-re/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/05/05/cathie-wood-loads-up-on-more-skillz-stock-after-re/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2133255365","content_text":"Mobile esports platform Skillz (NYSE:SKLZ) recorded yet another quarter of rising revenue, the 21st consecutive quarter in which revenue jumped year over year. And that was apparently enough for Wall Street's current investment guru, Cathie Wood, to load up again on its stock.\nWood's ARK Invest exchange-traded funds (ETFs) added another 3.1 million shares of Skillz yesterday (Wood's ETFs report their buys and sales daily), giving her nearly 15.6 million shares in total of the competitive-gameplay specialist.\n\nImage source: Getty Images.\nAlthough Skillz saw its revenue rise in the first quarter, it also reported wider losses for the period, with adjusted EBITDA coming in at a loss of $31.1 million, compared to losses of $14.6 million a year ago.\nStill, the esports company was able to exceed its own expectations on paying monthly average users (MAUs), which came in at 467,000, some 17,000 more than it guided for last quarter. However, that was below the upper end of Wall Street's forecast of 469,000 MAUs.\nLast month, short-seller Eagle Eye Research issued a report questioning Skillz's revenue-recognition policies. Another short-seller, Wolfpack Research, questioned the value of its recent deal with the National Football League.\nCathie Wood ended up coming to Skillz's defense, saying the allegations were \"either exaggerated or incorrect\" and stemmed from not understanding the esports company's business.\nWood's ARK Next Generation Internet ETF (NYSEMKT:ARKW) now owns 7.05 million shares of Skillz; her ARK Innovation (NYSEMKT:ARKK) owns over 8.51 million shares.\nWhile her purchases are yet another vote of confidence for Skillz, they don't comprise a particularly large portion of her funds' portfolios, amounting to no more than 1.92% in either of the two funds.","news_type":1},"isVote":1,"tweetType":1,"viewCount":742,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":374492331,"gmtCreate":1619475085323,"gmtModify":1634273253396,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"buy ?[微笑]&nbsp;","listText":"buy ?[微笑]&nbsp;","text":"buy ?[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/374492331","repostId":"1194765641","repostType":4,"repost":{"id":"1194765641","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1619450804,"share":"https://www.laohu8.com/m/news/1194765641?lang=&edition=full","pubTime":"2021-04-26 23:26","market":"us","language":"en","title":"Starbucks Stock Reported Mixed Earnings Results, Is It A Buy Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=1194765641","media":"Investors","summary":"Seattle-basedStarbucks(SBUX) emerged as a coffeehouse giant in the 1990s with a meteoric rise, evolv","content":"<p>Seattle-based<b>Starbucks</b>(SBUX) emerged as a coffeehouse giant in the 1990s with a meteoric rise, evolving from a local concept into a global brand. Amid the current stock market rally, is Starbucks stocka buy?</p>\n<p>Starbucks Earnings</p>\n<p>In themost recent quarter— reported on Jan. 26 — Starbucks reported mixed fiscal Q1 results and gave weak Q2 views despite a forecast for China same-store sales to nearly double.</p>\n<p>Starbucks reported EPS of 61 cents on revenue of $6.75 billion. Wall Street expected Starbucks earnings per share to fall 30% to 55 cents, according to Zacks Investment Research. Revenue was seen tilting 3% lower to $6.87 billion.</p>\n<p>According to theIBD Stock Checkup,Starbucksstock has a weak 37 out of a highest-possible 99 IBD Composite Rating. TheComposite Ratingis designed to help investors easily measure a stock's fundamental and technical characteristics.</p>\n<p>Fundamentally, the company boasts a deteriorating track record of earnings growth, resulting in a 33 (out of a best-possible 99) EPS Rating. TheEPS Ratingmeasures a company's current quarterly earnings and annual earnings growth.</p>\n<p>Starbucks Stock News</p>\n<p>On March 15, amid the spreading coronavirus outbreak,Starbucks movedinto a \"to-go\" model for its stores in the U.S. and Canada for at least two weeks. Starbucks also said some of its stores in \"high-social gathering\" areas will be shuttered to help prevent the spread of the virus.&nbsp;The moves came in the wake of the U.S. government's call for more social distancing.</p>\n<p>On April 16, Starbucksannounced plans to reopenstores that closed during the coronavirus outbreak. In a letter to employees, CEO Kevin Johnson said, \"As we have experienced in China, we are now transitioning to a new phase that can best be described as 'monitor and adapt.\"</p>\n<p>In late April, the company said it would start reopening U.S. stores as soon as early May, with plans to have around 90% of company-run locations open by early June with modified hours and more safety measures, but management said \"routines may look a little bit different\" even for its most loyal customers.</p>\n<p>On May 4, the&nbsp;the coffee giant said it plans to reopen more than 85% of its U.S. corporate stores by end of this week. Dine-in services will remain closed for the time being.</p>\n<p>In a letter to employees on May 21, CEO Kevin Johnson said the company has reclaimed about 60% to 65% of its U.S. same-store sales over the last week, vs. the same period a year ago.</p>\n<p>Starbucks CFO Patrick Grismer, during a conference in September, said the coffee giant was on track to reach positive same-store sales in the U.S. by the end of its fiscal second quarter.</p>\n<p>Is Starbucks Stock A Buy Right Now?</p>\n<p>During the coronavirus stock market crash, Starbucks shares fell nearly 50% off their 52-week high. After a sharp rally, the stock hit all-time highs on Jan. 4 before backing off. Starbucks is trying to break out above a 108.85 buy point in a new flat base, according toMarketSmithchart analysis. The 5% buy zone goes up to 114.29.</p>\n<p>Starbucks stock tumbled nearly 2% Monday despite a price-target hike at Stifel Nicolaus. The analyst firm raised its price target from 115 to 125. The stock remains out of buy range. So, Starbucks is no longer a potential buy right now since it's out of buy range. Meanwhile, a lack of strong fundamentals could be a deterrent to growth investors.</p>\n<p>For more leading stocks and stocks approaching buy points, check out these&nbsp;IBD Stock Lists, like the&nbsp;Stocks Near A Buy Zone.&nbsp;To see the current stock market trend, check out IBD's signature daily analysis,&nbsp;The Big Picture.</p>\n<p><i>Follow Scott Lehtonen on Twitter at @IBD_SLehtonen for more on stock market analysis and insight.</i></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Starbucks Stock Reported Mixed Earnings Results, Is It A Buy Right Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStarbucks Stock Reported Mixed Earnings Results, Is It A Buy Right Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-04-26 23:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Seattle-based<b>Starbucks</b>(SBUX) emerged as a coffeehouse giant in the 1990s with a meteoric rise, evolving from a local concept into a global brand. Amid the current stock market rally, is Starbucks stocka buy?</p>\n<p>Starbucks Earnings</p>\n<p>In themost recent quarter— reported on Jan. 26 — Starbucks reported mixed fiscal Q1 results and gave weak Q2 views despite a forecast for China same-store sales to nearly double.</p>\n<p>Starbucks reported EPS of 61 cents on revenue of $6.75 billion. Wall Street expected Starbucks earnings per share to fall 30% to 55 cents, according to Zacks Investment Research. Revenue was seen tilting 3% lower to $6.87 billion.</p>\n<p>According to theIBD Stock Checkup,Starbucksstock has a weak 37 out of a highest-possible 99 IBD Composite Rating. TheComposite Ratingis designed to help investors easily measure a stock's fundamental and technical characteristics.</p>\n<p>Fundamentally, the company boasts a deteriorating track record of earnings growth, resulting in a 33 (out of a best-possible 99) EPS Rating. TheEPS Ratingmeasures a company's current quarterly earnings and annual earnings growth.</p>\n<p>Starbucks Stock News</p>\n<p>On March 15, amid the spreading coronavirus outbreak,Starbucks movedinto a \"to-go\" model for its stores in the U.S. and Canada for at least two weeks. Starbucks also said some of its stores in \"high-social gathering\" areas will be shuttered to help prevent the spread of the virus.&nbsp;The moves came in the wake of the U.S. government's call for more social distancing.</p>\n<p>On April 16, Starbucksannounced plans to reopenstores that closed during the coronavirus outbreak. In a letter to employees, CEO Kevin Johnson said, \"As we have experienced in China, we are now transitioning to a new phase that can best be described as 'monitor and adapt.\"</p>\n<p>In late April, the company said it would start reopening U.S. stores as soon as early May, with plans to have around 90% of company-run locations open by early June with modified hours and more safety measures, but management said \"routines may look a little bit different\" even for its most loyal customers.</p>\n<p>On May 4, the&nbsp;the coffee giant said it plans to reopen more than 85% of its U.S. corporate stores by end of this week. Dine-in services will remain closed for the time being.</p>\n<p>In a letter to employees on May 21, CEO Kevin Johnson said the company has reclaimed about 60% to 65% of its U.S. same-store sales over the last week, vs. the same period a year ago.</p>\n<p>Starbucks CFO Patrick Grismer, during a conference in September, said the coffee giant was on track to reach positive same-store sales in the U.S. by the end of its fiscal second quarter.</p>\n<p>Is Starbucks Stock A Buy Right Now?</p>\n<p>During the coronavirus stock market crash, Starbucks shares fell nearly 50% off their 52-week high. After a sharp rally, the stock hit all-time highs on Jan. 4 before backing off. Starbucks is trying to break out above a 108.85 buy point in a new flat base, according toMarketSmithchart analysis. The 5% buy zone goes up to 114.29.</p>\n<p>Starbucks stock tumbled nearly 2% Monday despite a price-target hike at Stifel Nicolaus. The analyst firm raised its price target from 115 to 125. The stock remains out of buy range. So, Starbucks is no longer a potential buy right now since it's out of buy range. Meanwhile, a lack of strong fundamentals could be a deterrent to growth investors.</p>\n<p>For more leading stocks and stocks approaching buy points, check out these&nbsp;IBD Stock Lists, like the&nbsp;Stocks Near A Buy Zone.&nbsp;To see the current stock market trend, check out IBD's signature daily analysis,&nbsp;The Big Picture.</p>\n<p><i>Follow Scott Lehtonen on Twitter at @IBD_SLehtonen for more on stock market analysis and insight.</i></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SBUX":"星巴克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194765641","content_text":"Seattle-basedStarbucks(SBUX) emerged as a coffeehouse giant in the 1990s with a meteoric rise, evolving from a local concept into a global brand. Amid the current stock market rally, is Starbucks stocka buy?\nStarbucks Earnings\nIn themost recent quarter— reported on Jan. 26 — Starbucks reported mixed fiscal Q1 results and gave weak Q2 views despite a forecast for China same-store sales to nearly double.\nStarbucks reported EPS of 61 cents on revenue of $6.75 billion. Wall Street expected Starbucks earnings per share to fall 30% to 55 cents, according to Zacks Investment Research. Revenue was seen tilting 3% lower to $6.87 billion.\nAccording to theIBD Stock Checkup,Starbucksstock has a weak 37 out of a highest-possible 99 IBD Composite Rating. TheComposite Ratingis designed to help investors easily measure a stock's fundamental and technical characteristics.\nFundamentally, the company boasts a deteriorating track record of earnings growth, resulting in a 33 (out of a best-possible 99) EPS Rating. TheEPS Ratingmeasures a company's current quarterly earnings and annual earnings growth.\nStarbucks Stock News\nOn March 15, amid the spreading coronavirus outbreak,Starbucks movedinto a \"to-go\" model for its stores in the U.S. and Canada for at least two weeks. Starbucks also said some of its stores in \"high-social gathering\" areas will be shuttered to help prevent the spread of the virus. The moves came in the wake of the U.S. government's call for more social distancing.\nOn April 16, Starbucksannounced plans to reopenstores that closed during the coronavirus outbreak. In a letter to employees, CEO Kevin Johnson said, \"As we have experienced in China, we are now transitioning to a new phase that can best be described as 'monitor and adapt.\"\nIn late April, the company said it would start reopening U.S. stores as soon as early May, with plans to have around 90% of company-run locations open by early June with modified hours and more safety measures, but management said \"routines may look a little bit different\" even for its most loyal customers.\nOn May 4, the the coffee giant said it plans to reopen more than 85% of its U.S. corporate stores by end of this week. Dine-in services will remain closed for the time being.\nIn a letter to employees on May 21, CEO Kevin Johnson said the company has reclaimed about 60% to 65% of its U.S. same-store sales over the last week, vs. the same period a year ago.\nStarbucks CFO Patrick Grismer, during a conference in September, said the coffee giant was on track to reach positive same-store sales in the U.S. by the end of its fiscal second quarter.\nIs Starbucks Stock A Buy Right Now?\nDuring the coronavirus stock market crash, Starbucks shares fell nearly 50% off their 52-week high. After a sharp rally, the stock hit all-time highs on Jan. 4 before backing off. Starbucks is trying to break out above a 108.85 buy point in a new flat base, according toMarketSmithchart analysis. The 5% buy zone goes up to 114.29.\nStarbucks stock tumbled nearly 2% Monday despite a price-target hike at Stifel Nicolaus. The analyst firm raised its price target from 115 to 125. The stock remains out of buy range. So, Starbucks is no longer a potential buy right now since it's out of buy range. Meanwhile, a lack of strong fundamentals could be a deterrent to growth investors.\nFor more leading stocks and stocks approaching buy points, check out these IBD Stock Lists, like the Stocks Near A Buy Zone. To see the current stock market trend, check out IBD's signature daily analysis, The Big Picture.\nFollow Scott Lehtonen on Twitter at @IBD_SLehtonen for more on stock market analysis and insight.","news_type":1},"isVote":1,"tweetType":1,"viewCount":361,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":185473391,"gmtCreate":1623670574913,"gmtModify":1634030411724,"author":{"id":"3581852273201777","authorId":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;","listText":"[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;","text":"[微笑] [微笑] [微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185473391","repostId":"2141453253","repostType":4,"repost":{"id":"2141453253","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623096780,"share":"https://www.laohu8.com/m/news/2141453253?lang=&edition=full","pubTime":"2021-06-08 04:13","market":"us","language":"en","title":"Biogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK","url":"https://stock-news.laohu8.com/highlight/detail?id=2141453253","media":"Dow Jones","summary":"Shares rally to second -biggest one-day percentage gain since they went public 30 years agoShares of","content":"<p>Shares rally to second -biggest <a href=\"https://laohu8.com/S/AONE\">one</a>-day percentage gain since they went public 30 years ago</p><p>Shares of Biogen Inc. rocketed to a six-year high in volatile trading Monday, as Wall Street analysts cheered the U.S. Food and Drug Administration's broad labeling that came with the approval of the biotechnology company's Alzheimer's drug.</p><p>The stock <a href=\"https://laohu8.com/S/BIIB\">$(BIIB)$</a> blasted $109.71, or 38.3% higher, to $395.85, the highest close since April 2015. The stock had been halted twice for volatility  during Monday's session, once at 10:44 a.m. Eastern and a second time at 1:37 p.m.</p><p>Trading volume spiked up to 17.7 million shares, compared with the full-day average over the past 30 days of about 1.0 million shares, according to FactSet.</p><p>Earlier Friday, the FDA approved Biogen's Aduhelm , also known as aducanumab, to treat Alzheimer's, the first drug to be approved that promises to actually slow the disease rather than just treat the symptoms.</p><p>Biogen investors were treated to the stock's biggest-ever <a href=\"https://laohu8.com/S/AONE.U\">one</a>-day price gain, and second-biggest one-day percentage gain since it went public in September 1991. The stock had shot up $108.62, or 44.0%, on Nov. 4, 2020, after the FDA said there was \"substantial evidence\"</p><p>\"Currently available options only treat symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer's,\" said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research. \"As we have learned from the fight against cancer, the accelerated approval pathway can bring therapies to patients faster while spurring more research an innovation.\"</p><p>As the FDA described, accelerated approval can be based on the drug's effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients, with \"a required post-approval trial\" to verify the drug provides that expected clinical benefit.</p><p>Bernstein analyst Aaron Gal said approval under accelerated pathway is a distinction without a difference. \"The pathway allows for approval based on surrogate market, rather than completed efficacy endpoint data,\" Gal wrote in a note to clients. \"As long as Biogen does not challenge the use of the path, which they obviously would not, the approval holds.\"</p><p>Evercore ISI's Umer Raffat noted that the option of Accelerated Approval was not discussed by the FDA's advisory committee. And as the drug has \"clearly shown\" in all trials to substantially reduce amyloid beta plaques, the \"reduction in plaques is reasonably likely to result in clinical benefit.\"</p><p>Regarding labeling, Bernstein's Gal said it is \"almost shockingly broad,\" as the label just said Aduhelm is indicated for the treatment of Alzheimer's disease.</p><p>\"Thus, the approved population is broader than the tested population (mild-moderate Alzheimer's patients),\" Gal wrote. \"There is also no restriction on treatment duration suggesting that patients can stay on treatment until either all plaque is removed or the patient progresses.\"</p><p>Evercore's Raffat concurred, saying the label reads very very broad. He indicated that investors could be relieved, as there was some concern that the target population might be limited, and/or require very frequent monitoring.</p><p>Although pricing is still unknown, the Institute of Clinical and Economic Review (ICER) said that due to the relatively small overall health gains demonstrated in Phase 3 clinical trials, the drug should be price no higher than $8,400 a year, as MarketWatch's Jaimy Lee reported .</p><p>Some analysts say Biogen could price the drug higher than that, even though that might potentially trigger a regulatory response.</p><p>Evercore's Raffat said his financial estimates on Biogen include an estimate of $10,000, while Bernstein's Gal said the pricing could end up \"much higher,\" possibly as high as more than $30,000.</p><p>Gal said Biogen has a long history of pricing drugs in the \"specialty\" range, and is less likely to fear a backlash. \"Biogen would justify the price by arguing the total system impact would be modest upfront and that it will use the money to provide substantial services to [Alzheimer's disease] patients,\" Gal wrote.</p><p>Biogen and Eisai Inc., the U.S. subsidiary of Japan-based Eisai Co. Ltd. (4523.TO), announced after Aduhelm's approval programs intended to support access for all qualified patients, including those from traditionally underserved populations.</p><p>Eisai's U.S.-listed shares skyrocketed 68.9% in afternoon trading, on track for a record close and the biggest one-day gain since it started trading in the U.S. in December 1995.</p><p>\"We are committed to access and health equity as top priorities and will continue working with multiple stakeholders with the goal of helping patients who may benefit from treatment obtain care as quickly as possible,\" said Alisha Alaimo, president of Biogen U.S.</p><p>Biogen's stock has now run up 61.7% year to date, while SPDR Health Care Select Sector exchange-traded fund <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has gained 8.0% and the S&amp;P 500 index  has advanced 12.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-08 04:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares rally to second -biggest <a href=\"https://laohu8.com/S/AONE\">one</a>-day percentage gain since they went public 30 years ago</p><p>Shares of Biogen Inc. rocketed to a six-year high in volatile trading Monday, as Wall Street analysts cheered the U.S. Food and Drug Administration's broad labeling that came with the approval of the biotechnology company's Alzheimer's drug.</p><p>The stock <a href=\"https://laohu8.com/S/BIIB\">$(BIIB)$</a> blasted $109.71, or 38.3% higher, to $395.85, the highest close since April 2015. The stock had been halted twice for volatility  during Monday's session, once at 10:44 a.m. Eastern and a second time at 1:37 p.m.</p><p>Trading volume spiked up to 17.7 million shares, compared with the full-day average over the past 30 days of about 1.0 million shares, according to FactSet.</p><p>Earlier Friday, the FDA approved Biogen's Aduhelm , also known as aducanumab, to treat Alzheimer's, the first drug to be approved that promises to actually slow the disease rather than just treat the symptoms.</p><p>Biogen investors were treated to the stock's biggest-ever <a href=\"https://laohu8.com/S/AONE.U\">one</a>-day price gain, and second-biggest one-day percentage gain since it went public in September 1991. The stock had shot up $108.62, or 44.0%, on Nov. 4, 2020, after the FDA said there was \"substantial evidence\"</p><p>\"Currently available options only treat symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer's,\" said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research. \"As we have learned from the fight against cancer, the accelerated approval pathway can bring therapies to patients faster while spurring more research an innovation.\"</p><p>As the FDA described, accelerated approval can be based on the drug's effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients, with \"a required post-approval trial\" to verify the drug provides that expected clinical benefit.</p><p>Bernstein analyst Aaron Gal said approval under accelerated pathway is a distinction without a difference. \"The pathway allows for approval based on surrogate market, rather than completed efficacy endpoint data,\" Gal wrote in a note to clients. \"As long as Biogen does not challenge the use of the path, which they obviously would not, the approval holds.\"</p><p>Evercore ISI's Umer Raffat noted that the option of Accelerated Approval was not discussed by the FDA's advisory committee. And as the drug has \"clearly shown\" in all trials to substantially reduce amyloid beta plaques, the \"reduction in plaques is reasonably likely to result in clinical benefit.\"</p><p>Regarding labeling, Bernstein's Gal said it is \"almost shockingly broad,\" as the label just said Aduhelm is indicated for the treatment of Alzheimer's disease.</p><p>\"Thus, the approved population is broader than the tested population (mild-moderate Alzheimer's patients),\" Gal wrote. \"There is also no restriction on treatment duration suggesting that patients can stay on treatment until either all plaque is removed or the patient progresses.\"</p><p>Evercore's Raffat concurred, saying the label reads very very broad. He indicated that investors could be relieved, as there was some concern that the target population might be limited, and/or require very frequent monitoring.</p><p>Although pricing is still unknown, the Institute of Clinical and Economic Review (ICER) said that due to the relatively small overall health gains demonstrated in Phase 3 clinical trials, the drug should be price no higher than $8,400 a year, as MarketWatch's Jaimy Lee reported .</p><p>Some analysts say Biogen could price the drug higher than that, even though that might potentially trigger a regulatory response.</p><p>Evercore's Raffat said his financial estimates on Biogen include an estimate of $10,000, while Bernstein's Gal said the pricing could end up \"much higher,\" possibly as high as more than $30,000.</p><p>Gal said Biogen has a long history of pricing drugs in the \"specialty\" range, and is less likely to fear a backlash. \"Biogen would justify the price by arguing the total system impact would be modest upfront and that it will use the money to provide substantial services to [Alzheimer's disease] patients,\" Gal wrote.</p><p>Biogen and Eisai Inc., the U.S. subsidiary of Japan-based Eisai Co. Ltd. (4523.TO), announced after Aduhelm's approval programs intended to support access for all qualified patients, including those from traditionally underserved populations.</p><p>Eisai's U.S.-listed shares skyrocketed 68.9% in afternoon trading, on track for a record close and the biggest one-day gain since it started trading in the U.S. in December 1995.</p><p>\"We are committed to access and health equity as top priorities and will continue working with multiple stakeholders with the goal of helping patients who may benefit from treatment obtain care as quickly as possible,\" said Alisha Alaimo, president of Biogen U.S.</p><p>Biogen's stock has now run up 61.7% year to date, while SPDR Health Care Select Sector exchange-traded fund <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has gained 8.0% and the S&amp;P 500 index  has advanced 12.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2141453253","content_text":"Shares rally to second -biggest one-day percentage gain since they went public 30 years agoShares of Biogen Inc. rocketed to a six-year high in volatile trading Monday, as Wall Street analysts cheered the U.S. Food and Drug Administration's broad labeling that came with the approval of the biotechnology company's Alzheimer's drug.The stock $(BIIB)$ blasted $109.71, or 38.3% higher, to $395.85, the highest close since April 2015. The stock had been halted twice for volatility  during Monday's session, once at 10:44 a.m. Eastern and a second time at 1:37 p.m.Trading volume spiked up to 17.7 million shares, compared with the full-day average over the past 30 days of about 1.0 million shares, according to FactSet.Earlier Friday, the FDA approved Biogen's Aduhelm , also known as aducanumab, to treat Alzheimer's, the first drug to be approved that promises to actually slow the disease rather than just treat the symptoms.Biogen investors were treated to the stock's biggest-ever one-day price gain, and second-biggest one-day percentage gain since it went public in September 1991. The stock had shot up $108.62, or 44.0%, on Nov. 4, 2020, after the FDA said there was \"substantial evidence\"\"Currently available options only treat symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer's,\" said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research. \"As we have learned from the fight against cancer, the accelerated approval pathway can bring therapies to patients faster while spurring more research an innovation.\"As the FDA described, accelerated approval can be based on the drug's effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients, with \"a required post-approval trial\" to verify the drug provides that expected clinical benefit.Bernstein analyst Aaron Gal said approval under accelerated pathway is a distinction without a difference. \"The pathway allows for approval based on surrogate market, rather than completed efficacy endpoint data,\" Gal wrote in a note to clients. \"As long as Biogen does not challenge the use of the path, which they obviously would not, the approval holds.\"Evercore ISI's Umer Raffat noted that the option of Accelerated Approval was not discussed by the FDA's advisory committee. And as the drug has \"clearly shown\" in all trials to substantially reduce amyloid beta plaques, the \"reduction in plaques is reasonably likely to result in clinical benefit.\"Regarding labeling, Bernstein's Gal said it is \"almost shockingly broad,\" as the label just said Aduhelm is indicated for the treatment of Alzheimer's disease.\"Thus, the approved population is broader than the tested population (mild-moderate Alzheimer's patients),\" Gal wrote. \"There is also no restriction on treatment duration suggesting that patients can stay on treatment until either all plaque is removed or the patient progresses.\"Evercore's Raffat concurred, saying the label reads very very broad. He indicated that investors could be relieved, as there was some concern that the target population might be limited, and/or require very frequent monitoring.Although pricing is still unknown, the Institute of Clinical and Economic Review (ICER) said that due to the relatively small overall health gains demonstrated in Phase 3 clinical trials, the drug should be price no higher than $8,400 a year, as MarketWatch's Jaimy Lee reported .Some analysts say Biogen could price the drug higher than that, even though that might potentially trigger a regulatory response.Evercore's Raffat said his financial estimates on Biogen include an estimate of $10,000, while Bernstein's Gal said the pricing could end up \"much higher,\" possibly as high as more than $30,000.Gal said Biogen has a long history of pricing drugs in the \"specialty\" range, and is less likely to fear a backlash. \"Biogen would justify the price by arguing the total system impact would be modest upfront and that it will use the money to provide substantial services to [Alzheimer's disease] patients,\" Gal wrote.Biogen and Eisai Inc., the U.S. subsidiary of Japan-based Eisai Co. Ltd. (4523.TO), announced after Aduhelm's approval programs intended to support access for all qualified patients, including those from traditionally underserved populations.Eisai's U.S.-listed shares skyrocketed 68.9% in afternoon trading, on track for a record close and the biggest one-day gain since it started trading in the U.S. in December 1995.\"We are committed to access and health equity as top priorities and will continue working with multiple stakeholders with the goal of helping patients who may benefit from treatment obtain care as quickly as possible,\" said Alisha Alaimo, president of Biogen U.S.Biogen's stock has now run up 61.7% year to date, while SPDR Health Care Select Sector exchange-traded fund $(XLV)$ has gained 8.0% and the S&P 500 index  has advanced 12.5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":311,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}